186 drugs to be transferred out of health insurance (with list)

On June 4,, the Guangxi Zhuang Autonomous Region Medical Insurance Bureau issued a notice on the adjustment of the "Guangxi Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drug Catalog" noticenotice clearly:, the original Guangxi basic medical insurance, industrial injury insurance and maternity insurance drugs in the scope of payment of the provisions of the drug gradually digested within three years, from June 1, 2022 to implement the national basic medical insurance, industrial injury insurance and maternity insurance drug catalogueAdjust the specification of some drug names, classifications, dosage forms and limit the scope of paymentThis notice shall be implemented from June 1, 2020, and if it is inconsistent with the provisions of this notice, this notice shall prevailaccording to Seiber blue combing, in Guangxi this adjustment norms western medicine, traditional Chinese medicine part, 144 drugs were transferred out of the Western medicine part, 42 drugs were transferred out of the traditional Chinese medicine partin addition, a large number of drugs were required to implement a limited payment range in accordance with the national 2019 drug catalogue, and a small number of drugs were partially reimbursed dosage formsthe revised Guangxi "Drug Catalog" includes 1645 Western medicine stakes, 1759 Chinese traditional medicines (including 97 ethnic drugs), and 118 drugs negotiated during the agreement period (including 95 Western medicines and 23 Chinese medicines), for a total of 3522the number of drugs included in the regular access section of the 2019 edition of the National Medical Insurance Directory was 2,643, including 1,322 Western medicines, 1321 traditional Chinese medicines (including 93 ethnic medicines);april this year, it was revealed that the National Health Insurance Administration's Department of Pharmaceutical Prices and Tender procurement has issued a focus on 2020, on the management of medical insurance catalog, requireall all regions as soon as possible to develop a three-year digestion plan for additional varieties, by the end of June this year, the state key monitoring varieties out of the catalog, and complete the 40% of the province's supplementary varieties digestionOn February 5,, the State Administration of Health Insurance issued the "2020 Notice of The Key Points of Health Insurance Work" that referred to strengthening the management of the health insurance catalogue - establishing a dynamic adjustment mechanism for the catalogue of medical insurance drugs, strengthening supervision and dispatching, and promoting the digestion of self-supplemented varieties in various places according to scheduleon August 20 last year, the State Health Insurance Administration officially issued the 2019 edition of the National Medical Insurance Directory, and at the same time proposed: "all regions should strictly implement the Drug Catalog", not to develop their own catalogs or use alternative methods to increase the scope of payment of drugs in the catalogFor the original provincial drug catalogue in accordance with the provisions of the increase of Class B drugs, should be gradually digested within 3 yearsIn the process of digestion, the provinces shall give priority to the adjustment of the scope of payment of drugs that are included in the scope of national key monitoring"according to Seiber blue understanding, the local supplementary varieties transfer out of the medical insurance arrangements as follows:1, focus on monitoring the list of drugs to take the lead out of the medical insurance catalog;the 2019 health care catalog has been officially implemented since January 1 this yearAccording to the requirements of the National Health Insurance Administration, the provinces that docked the 2019 edition of the National Health Insurance Directory have explicitly proposed to remove state-focused surveillance drugs from the health insurance catalogaccording to The saiber blue statistics, there are at least 15 provinces and cities in Jiangxi, Shandong, Beijing, Hunan, Sichuan, Guangdong, Tianjin, Zhejiang, Anhui, Guangxi and other provinces and cities to the local health insurance catalog additions to the specific release, 4 provinces and cities on the local health insurance supplementary varieties to give specific directory or guidance, many provinces and cities have published the transfer listOn April 22,, Anhui Provincial Health Insurance Bureau announced a draft of the draft for the digestion of the local medical insurance drug catalogue, explaining the varieties transferred from the provincial medical insurance catalogueAnhui Province has announced two specific points of time:the publication of priority digested drugs in June 2020, all digestive varieties by the end of December 2020, and a specific time to withdraw from the scope of medical payments in Anhui ProvinceDuring the three-year digestion period, if the relevant national policies are adjusted, they shall be implemented in accordance with the national regulations, the Jiangxi Provincial Health Insurance Bureau has established the Jiangxi Province TransitionAl Reserve Drug Catalog, including 22 Western medicines and 46 traditional Chinese medicines that exceed the "National New Edition Catalog", with a retention period of 12 December 2020 and June 30, 2022, respectively, and will be removed directly from the medical insurance catalogue after the expiration dateShandong Provincial Health Insurance Bureau has announced three years of gradual digestion of medical insurance varieties, a total of 268, of which 143 Western medicine, 125 traditional Chinese medicineHunan Provincial Health Insurance Bureau also issued a notice to determine the "digestion period of the drug part", a total of 404 varietiesThis part of the variety will be digested year by year in accordance with the provisions of the state, clearing out the scope of medical insurance the Beijing Municipal Health Insurance Bureau issued a notice, clearly remove the drugs removed from the national medical insurance drug catalogue of sodium pasobicarbonate oral asanobie and the scope of national key state medical insurance drugs, a total of 352 varieties, including 281 Western medicine and 71 traditional Chinese medicine Hebei Province Medical Insurance Bureau also issued a clear, the original addition of Class B drugs, priority out of the national and provincial key monitoring scope of drugs, the formation of a temporary reservation of the provincial supplementary drug catalog, the provincial medical security bureau will be gradually digested within three years There are 498 varieties in the provincial supplementary catalogue, including 286 Western medicines and 212 traditional Chinese medicines is the same as a direct loss of eligibility for medical insurance reimbursement for the varieties that have been transferred out of the local health insurance supplementary list With the increase of the national health insurance catalog adjustment frequency, some drugs with high price, inaccurate clinical efficacy and obvious therapeutic advantage will also face the pressure of losing medical insurance reimbursement On April 29, , the official website of the State Administration of Medical Security issued the Interim Measures for the Administration of Drug Use in Basic Medical Insurance (Draft for Comments) for public comments, which made it clear that the National Health Insurance Directory would be dynamically adjusted, in principle, once a year 2019 edition of the National Health Insurance Directory compared to the previous edition, a total of 150 varieties, about half of which are the State Drug Administration to withdraw the number of drugs, the rest are mainly clinical value is not high, abuse is obvious, there is a better alternative drug the state health insurance bureau issued a draft of the opinion further clarified the specific conditions for drugs to be transferred out of the medical insurance catalogue: drugs in the "Drug Catalog", if there are one of the following cases, after expert evaluation, directly transferred out of the Drug Catalog: (1) by the drug regulatory authorities to revoke, revoke or cancel the drug approval document s of the drug; Drugs sold and used; (3) drugs listed by relevant departments and institutions; (4) taking into account clinical value, adverse reactions, drug economy and other factors, which are assessed as risk-exceeding than the benefits, drugs (5) entering the Drug Catalog through illegal means such as fraud; and other situations that should be directly transferred by the (6) State provisions In addition, the , the draft also stipulates that the following drugs are not included in the Drug List: drugs that mainly tonic; drugs containing national precious and endangered wildlife medicines; health drugs; Class B OTC drugs; tablets reprocessed on standard drink tablets, such as wall-to-wall and refined tablets; preventive vaccines and contraceptives; and mainly enhanced function, enhanced function, Drugs for the treatment of hair loss, weight loss, beauty, smoking cessation, alcohol withdrawal, etc.; diagnostic reagents, test reagents, etc., included in the treatment and treatment items charged; wine preparations, tea preparations, all kinds of fruit-flavoured preparations (except children's medications in special cases), oral medications and oral foaming agents (except special provisions), etc.; side is the policy requires the gradual digestion of local medical insurance supplementary varieties, a large number of drugs will lose local reimbursement qualifications; in the context of the overall more dynamic health insurance adjustment, the relevant pharmaceutical companies must be closer to the value of medical insurance, pay attention to the clinical safety and effectiveness of drug use, and further improve the cost-effective products